Navigation Links
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Date:4/2/2009

and technical issues; clinical trials, including the DURATION-2 clinical trial mentioned in this press release, not being completed in a timely manner, not confirming previous results, or not achieving the intended clinical endpoints; pre-clinical trials not predicting future results; label expansion requests or New Drug Application ("NDA") filings, including the NDA filing for exenatide once weekly, not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA, SYMLIN and/or exenatide once weekly may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products. These risks also include a potential adverse impact on our financial condition if the steps outlined in this press release to address the change of control provisions in two of our debt agreements are unsuccessful and we are required to repay the amounts outstanding under any of our debt agreements. These and additional risks and uncertainties are described more fully in Amylin's most recent SEC filings including its Annual Report on Form 10-K. Amylin undertakes no duty to update these forward-looking statements.

Additional Information and Where to Find It

This release may be deemed to be solicitation material in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Amylin will be filing a proxy statement with the Securities and Exchange Commission ("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE BLUE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and securityholders will be able to receive the proxy statement and other re
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... (PRWEB) September 12, 2014 RURO, ... radio-frequency identification (RFID) solutions and sample management solutions ... , RURO completed work on the most recent ... and it has already seen mass adoption, especially ... release of version 5.0 brought an entirely new ...
(Date:9/11/2014)... Researchers at Chalmers University of Technology are first to ... artificial atom. They can thereby demonstrate phenomena from quantum ... The results will be published in the journal ... is well known and has been studied extensively in ... same kind of interaction with sound waves has been ...
(Date:9/11/2014)... Texas , Sept. 11, 2014 XBiotech ... high throughput filling machine that the Company says will ... The fully integrated system is designed to fill, stopper ... the manufacturing process. Additionally, the unit is said to ... scanning system to provide a high level of quality ...
(Date:9/11/2014)... Until recently, pets suffering from arthritic ... ease their pain. Pill therapies are costly, can be ... relief. , The procedure uses adult (not embryonic) ... own regenerative healing power. MediVet's equipment enable veterinarians to ... the stem cells, then activate and inject the cells ...
Breaking Biology Technology:Limfinity® Version 5.1 Available 2The sound of an atom has been captured 2MediVet America Secures Exclusive Worldwide License with Nanofiber Veterinary 2
... that since few people can afford to travel outside the country ... ultra safe adult stem cell treatments to alleviate the suffering of ... ... Thailand (PRWEB) March 31, 2009 -- Don Margolis, founder of the ...
... (Nasdaq: BSTC ), a biopharmaceutical company developing ... results for the fourth quarter and full year ended ... that our partner Auxilium has been advancing XIAFLEX(TM) through ... trial in Peyronie,s disease as well submitting a Biologics ...
... N.Y., March 30 Double Helix Consulting US, ... today announced the appointment of Ann Stuchiner to ... a multidisciplinary team of highly experienced strategic pricing, ... across the healthcare industry, which provide product commercialization ...
Cached Biology Technology:Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 2Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 7Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division 2
(Date:9/11/2014)... the genus Calathus , 17 of which have only ... scientists have found two new ones Calathus juan ... them in Annals of the Entomological Society of America ... Novoa, the son of one of the authors, in recognition ... and shiny, and are 9.5-11.5 millimeters long. It was found ...
(Date:9/11/2014)... to horns, humans have long been fascinated by ... weapons. But until now, no studies have directly ... animals, own style of fighting than they would ... at the University of Montana recently discovered each ... own functional demands of fighting., The groundbreaking research, ...
(Date:9/11/2014)... Nanyang Technological University (NTU) has developed a first-of-its-kind ... savings and superior performance, the new invention has ... water industry obsolete. , This made-in-NTU membrane lasts ... is highly resistant to breakage, and has anti-bacterial ... allows for an unprecedented flow rate of at ...
Breaking Biology News(10 mins):UM research reveals secrets of animal weapons 2​NTU spin-off achieves breakthrough with innovative multifunction membranes 2​NTU spin-off achieves breakthrough with innovative multifunction membranes 3
... single protein is critical in the cellular export of ... in the March issue of Cell Metabolism. , Hemochromatosis--which ... Western populations --causes tissues of the body to become ... lead to organ failure. , The new work, led ...
... protects the body's infection-fighting cells might also contribute to ... disease, UT Southwestern Medical Center researchers have found. , ... inhibits cell death in macrophages, which circulate in the ... foreign substances. The AIM-protected macrophages go on to encourage ...
... There are 300 million cases of malaria each year ... deaths occur in Africa, mostly in young children. One ... against malaria is drug resistance; resistance to chloroquine (CQ), ... throughout Africa, and resistance to sulfadoxine-pyrimethamine (SP), the first-developed ...
Cached Biology News:Iron exporter revealed that may explain common human disorder 2Iron exporter revealed that may explain common human disorder 3Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries 2Reducing malarial transmission in Africa 2
... expression of an N-terminal FLAG® fusion and ... marker from bicistronic mRNA. Two genes ... for transcription of a single message from ... for protein-protein interaction studies, multi-subunit proteins, and ...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: